Gengfu Xiao

机构：Chinese Academy of Sciences, Wuhan Institute of Virology, University of Chinese Academy of Sciences · ORCID：0000-0001-9401-235X

发表论文 148 篇 · 总被引 22507 次 · h-index 43

代表论文

• Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir (2023 · Nature Communications · 被引 115)
• Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2 (2023 · Cell Discovery · 被引 67)
• CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus (2023 · Science Advances · 被引 52)
• High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors (2022 · Protein & Cell · 被引 30)
• A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir (2023 · Signal Transduction and Targeted Therapy · 被引 26)
• A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses (2024 · Journal of Virology · 被引 24)